Tabula Rasa HealthCare Calls for an Extension of the CMMI Enhanced Medication Therapy Management Model to Enhance the Safety of Medicare Beneficiaries

Rhea-AI Summary

Tabula Rasa HealthCare (TRHC) has joined a coalition of 37 organizations urging the U.S. Department of Health and Human Services to extend the Center for Medicare & Medicaid Innovation's Enhanced Medication Therapy Management (EMTM) Model, which is set to expire on December 31, 2021. The EMTM Model aims to improve beneficiary outcomes, lower Medicare spending, and reduce medication-related risks. Since its launch in 2017, the initiative has shown promise in enhancing health outcomes and decreasing medical costs for Medicare Part D beneficiaries.

Positive

• Membership in a coalition advocating for the EMTM Model extension.
• Demonstrated improvements in patient outcomes and lowered healthcare costs since the EMTM Model's inception.

Negative

• Uncertainty regarding the future of the EMTM Model as it approaches its December 31, 2021 expiration date.

MOORESTOWN, N.J., July 28, 2021 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.^® (TRHC) (NASDAQ: TRHC), today joined a coalition of 37 physician, pharmacy, patient advocacy, health care quality, managed care, and academic associations, companies, and institutions calling upon the U.S. Department of Health and Human Services (HHS) to extend the Center for Medicare & Medicaid Innovation's (CMMI) Part D Enhanced Medication Therapy Management (EMTM) Model currently set to sunset on December 31, 2021.

In an effort to identify opportunities to improve beneficiary outcomes in the traditional Part D MTM program, CMMI launched the EMTM Model on January 1, 2017, with the goal of aligning incentives, lowering overall Medicare spending, and reducing medication risk for enrollees.

Since its inception, the innovations and clinical resources funded by the Model have helped to improve the safe use of medications for enrolled Medicare Part D beneficiaries. Many EMTM interventions have also demonstrated improved health outcomes and lower medical spending across Medicare Parts A and B.

"The EMTM Model encourages collaboration and alignment among plan sponsors, pharmacists, and physicians, to help significantly improve the health outcomes of patients, especially our most vulnerable populations, beyond the traditional Part D MTM programs," said TRHC Chairman and CEO Calvin H. Knowlton, PhD. "We at TRHC believe it is critical to expand this program to further advance the lessons and opportunities uncovered by the EMTM Model."

The members of the coalition are asking Department of Health and Human Services to extend or expand this important program to ensure safe use of medications for millions of Americans on Medicare. Specifically, they strongly urge HHS to apply key flexibilities from the EMTM Model to the national Part D Medication Therapy Management Program (MTMP); to allow plan sponsors to implement innovative best practices currently unavailable in MTMP; and to extend the current CMMI EMTM Model beyond the current end date to better understand the full savings and quality improvement implications of the first 5 years, without disrupting current recipients, programs, and investments.

"I strongly believe we need to urge HHS Secretary Xavier Becerra to extend the CMS' Enhanced Medication Therapy Management (EMTM) program, which is significantly improving therapeutic outcomes at lower costs in vulnerable and low-income Medicare patients," said John C. "Jack" Lewin MD, Chairman, National Coalition on Health Care. "This program has not had time to demonstrate its full worth." 

About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) (NASDAQ: TRHC) provides medication safety solutions that empower healthcare professionals and consumers to optimize medication regimens, combatting medication overload and reducing adverse drug events – the fourth leading cause of death in the US. TRHC's proprietary technology solutions, including MedWise^®, improve patient outcomes, reduce hospitalizations, and lower healthcare costs. TRHC's extensive clinical tele-pharmacy network improves care for patients nationwide. Its solutions are trusted by health plans and pharmacies to help drive value-based care. For more information, visit TRHC.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tabula-rasa-healthcare-calls-for-an-extension-of-the-cmmi-enhanced-medication-therapy-management-model-to-enhance-the-safety-of-medicare-beneficiaries-301343325.html

SOURCE Tabula Rasa HealthCare, Inc.

FAQ

What is the CMMI Enhanced Medication Therapy Management Model and how does it affect Medicare beneficiaries?

The CMMI Enhanced Medication Therapy Management Model is designed to improve health outcomes for Medicare beneficiaries by enhancing collaboration among healthcare providers, ultimately aiming to lower Medicare costs.

What are the key points of Tabula Rasa HealthCare's recent press release about the EMTM Model?

TRHC advocates for the extension of the EMTM Model, emphasizing its role in improving medication safety and health outcomes for Medicare beneficiaries.

What impact has the EMTM Model had since its launch in 2017?

Since its launch, the EMTM Model has reportedly improved patient outcomes and reduced medical spending among Medicare beneficiaries.

Why is TRHC calling for an extension of the EMTM Model?

TRHC believes further extension is necessary to fully realize the benefits and savings identified through the EMTM Model.

When is the current expiration date for the CMMI EMTM Model?

The current expiration date for the CMMI EMTM Model is December 31, 2021.